News articles about Nuvectra (NASDAQ:NVTR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nuvectra earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.2253238776724 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Nuvectra (NVTR) opened at $9.65 on Tuesday. Nuvectra has a one year low of $5.39 and a one year high of $15.00. The stock has a market cap of $104.07 and a price-to-earnings ratio of -2.05. The company has a current ratio of 2.90, a quick ratio of 2.72 and a debt-to-equity ratio of 0.37.

Nuvectra (NASDAQ:NVTR) last released its earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.07. The company had revenue of $7.60 million during the quarter, compared to the consensus estimate of $8.08 million. Nuvectra had a negative net margin of 204.19% and a negative return on equity of 68.63%. The company’s revenue was up 100.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.92) EPS. analysts expect that Nuvectra will post -4.58 earnings per share for the current fiscal year.

Several research firms recently issued reports on NVTR. ValuEngine downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Piper Jaffray Companies reaffirmed a “hold” rating and set a $12.00 price target on shares of Nuvectra in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. Nuvectra currently has a consensus rating of “Hold” and an average target price of $12.00.

TRADEMARK VIOLATION WARNING: “Nuvectra (NVTR) Getting Somewhat Positive Media Coverage, Accern Reports” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at

Nuvectra Company Profile

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Insider Buying and Selling by Quarter for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with's FREE daily email newsletter.